Dernières nouvelles pour Permian Resources (NYSE:PR) Stock

Permian Resources

Permian Resources Corp is an independent oil and natural gas company focused on generating outsized returns to stakeholders through the responsible acquisition, optimization and development of oil and liquids-rich natural gas assets. The Company's assets and operations are primarily concentrated in the core of the Permian Basin, and its properties consist of large, contiguous acreage blocks located in West Texas and New Mexico.

Permian Resources Corporation Class A Common Stock

Permian Resources Corp

ProAssurance Corp

PRA Group Inc

PRODUCTIVITY TECHS CORP by Productivity Technologies Corp.

Productivity Technologies Corp

Northern Lights Fund Trust III PlanRock Alternative Growth ETF

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicines Inc

NEOS ETF Trust FIS Christian Stock Fund

PRECISE BIOMETRICS AB by Precise Biometrics AB

Precise Biometrics AB

Parabellum Acquisition Corp Class A

Parabellum Acquisition Corp Units (1 Ord Share Class A & 3/4 War)

Parabellum Acquisition Corp Warrants(01/01/9999)

PREMIUM BRANDS HOLDINGS by Premium Brands Holding Corp.

Premium Brands Holdings Corp

PROTEIN REACTOR COMBINED by Protein Reactor Combined Fuels Inc

Protein Reactor Combined Fuels Inc

Porch Group Inc

PLACER CREEK MINING CO by Placer Creek Mining Co.

Placer Creek Mining Co

Parcl - United States dollar

PURE GLOBAL CANNABIS INC by Pure Global Cannabis Inc.

Pure Global Cannabis Inc

Procurri Corp Ltd

Parnassus Income Funds Parnassus Core Select ETF

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics Corp

PHOENIX RISING COS by PHOENIX RISING COS.

Phoenix Rising Co

GREEN CROSS HLTH LTD by Green Cross Health Ltd

Green Cross Health Ltd

Premier Diversified Holdings Inc

PARADOX INTERACTIVE U/ADR by Paradox Interactive AB

Paradox Interactive AB

PROFITABLE DEVELOPMENTS by Profitable Developments, Inc.

Profitable Developments Inc

Perdoceo Education Corporation - Common Stock

Perdoceo Education Corp

PARDES BIOSCIENCES INC COM

Prada SpA

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global Ltd

Presearch

PRESTIGE CARS INTL by Prestige Cars International, Inc.

Prestige Cars International Inc

Predictive Technology Group Inc

PREDICTIVE TECH GROUP INC by Predictive Technology Group, Inc.

Principal Spectrum Preferred Securities Active ETF

PRECIPITATE GOLD CORP by Precipitate Gold Corp

Precipitate Gold Corp

PARTNERRE PFD SHS SER J by PartnerRe Ltd.

PartnerRe Ltd

PRAIRIESKY ROYALTY LTD by Prairiesky Royalty Ltd.

PrairieSky Royalty Ltd

PERPETUAL RES LTD ORD by Perpetual Resources Limited

Perpetual Resources Ltd

Pennsylvania Real Estate Investment Trust

Pennsylvania Real Estate Investment Trust 7 3/8 % Cum Red Perp Pfd Shs Series -B-

Pennsylvania Real Estate Investment Trust 7.20% Cum Red Perp Registered Pfd Shs Series -C-

Pennsylvania Real Estate Investment Trust 6.875% Cum Red Perp Pfd Shs Series -D-

Prosperity Real Estate Investment Trust

POWER RESOURCE EXPL INC by Power Resource Exploration Inc.

Power Resource Exploration Inc

Invesco FTSE RAFI US 1000 ETF

PIMCO U.S. Treasury Index Fund PIMCO Preferred and Capital Securities Active Exchange-Traded Fund

PERFICIENT INC COM

PROSPEROUS FUTURE HLDGS by PROSPEROUS FUTURE HLDGS LTD.

Prosperous Future Holdings Ltd

PainReform Ltd

Invesco FTSE RAFI US 1500 Small-Mid ETF

PROG Holdings Inc

PUREGOLD PRICE CLUB ADR by Puregold Price Club Inc.

Puregold Price Club Inc

PARAGON SHIPPING CL A ORD by Paragon Shipping, Inc.

Paragon Shipping Inc

Perrigo Co PLC

Progress Software Corporation - Common Stock

Progress Software Corp

Prudential Financial, Inc. 5.950% Junior Subordinated Notes due 2062

PREMIER HEALTH AMER INC by PREMIER HEALTH AMER INC.

PURE H2O BIO-TECHS by Pure H2O Bio-Technologies Inc.

Pure H2O Bio-Technologies Inc

Primerica Inc

Prime Impact Acquisition I Ordinary Shares - Class A

PRIORITY INCOME FD STIRA by Priority Income Fund Inc.

Priority Income Fund, Inc.

Priority Income Fund, Inc. 7.00% Series D Term Preferred Stock due 2029

Priority Income Fund, Inc. 6.625% Series F Term Preferred Stock due 2027

Priority Income Fund, Inc. 6.25% PRF REDEEM 30/06/2026 USD 25 - Ser G

Priority Income Fund, Inc. 6.00% Series H Term Preferred Stock due 2026

Priority Income Fund, Inc. 6.125% Series I Term Preferred Stock due 2028

Priority Income Fund, Inc. 6.000% Series J Term Preferred Stock due 2028

Priority Income Fund, Inc. 7.000% Series K Cumulative Preferred Stock

Priority Income Fund, Inc. 6.375% Series L Term Preferred Stock Due 2029

Primoris Services Corporation Common Stock

Primoris Services Corp

Prime - United States dollar

Prism

Prime Impact Acquisition I Warrants (01/10/2030)

Park National Corp

PARKS! AMERICA INC by Parks! America, Inc.

Parks! America Inc

PARKER CORP by Parker Corp.

PERK INTERNATIONAL INC by Perk International Inc

Perk International Inc

Parkervision Inc

United Parks & Resorts Inc

PARKVIDA GROUP INC by ParkVida Group, Inc.

ParkVida Group Inc

Parkway Life Real Estate Investment Trust

Proto Labs Inc

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics Inc

Pillarstone Capital REIT

Pillarstone Capital REIT 9.50% PRF PERPETUAL USD 10 - Cls A9.50% PRF PERPETUAL USD 10 - Cls A

PILLARSTONE CAPITAL REIT by Pillarstone Capital REIT

Pearl Holdings Acquisition Corp Ordinary Shares - Class A

Pearl Holdings Acquisition Corp

Pearl Holdings Acquisition Corp Units (1 Ord Share Class A & 1/2 War)

Pearl Holdings Acquisition Corp Warrants (15/12/2026)

PIRELLI & C SPA UNSP/ADR by Pirelli & C. SpA

Pirelli & C SpA

PROLOGIC MGMT SYSTEMS INC by Prologic Management Systems, Inc.

Prologic Management Systems Inc

Propel Holdings Inc

PILLARSTONE CPTL REIT PFD by Pillarstone Capital REIT

Perimeter Solutions Inc

Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) has outperformed the market over the past 5 years by 6.31% on an annualized basis producing an average annual return of 18.79%. Currently, Williams Companies has a market capitalization of $69.22 billion. 
Buying $1000 In WMB: If an investor had bought $1000 of WMB stock 5 years ago, it would be worth $2,371.32 today based on a price of $56.78 for WMB at the time of writing.
<h3>Williams Companies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736452810_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In Williams Companies 5 Years Ago Would Be Worth This Much Today

Electric vehicle company BYD Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) is launching the first electric vehicle to come with a starting price under $30,000 in Australia, a move that could boost the country's <a href="https://www.benzinga.com/electric-vehicles">electric vehicle market.</a>
What Happened: Along with investing in blue-chip U.S. companies, Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) CEO Warren Buffett has recognized the investment opportunity<a href="https://www.benzinga.com/news/financing/24/12/42535041/warren-buffett-gains-exposure-to-digital-banks-in-africa-south-america-heres-how"> in emerging markets.</a>
One of Buffett's investments is owning a stake in Chinese company BYD, a global leader in electric vehicle. While Buffett has <a href="https://www.benzinga.com/markets/equities/24/06/39481191/warren-buffets-berkshire-drops-byd-stake-despite-ev-leader-seeing-record-sales">sold a portion</a> of the company's stake in BYD, Berkshire still owns around 4.9% of the company, representing around $1.8 billion in the Berkshire portfolio.
BYD could see a boost to its growth in 2025 thanks to the launch of a new version of its popular Dolphin EV in Australia.
A new stripped-down version of the Dolphin comes with a starting price of $29,900 in Australia, as <a href="https://electrek.co/2025/01/08/byd-just-launched-first-ev-priced-under-30000-australia/">reported </a>by Electrek, <a href="https://www.smh.com.au/politics/federal/chinese-giant-brings-first-ev-for-under-30-000-to-australia-20250108-p5l2vb.html">citing </a>The Sydney Morning Herald.
BYD has launched models like the Dolphin, Atto 3 and Seagull in Australia over the years and it now has the cheapest EV in the country, replacing the previous record of $30,990 by the MG4, which later raised its price to $38,000.
The lower-cost model does not include some normal Dolphin features like a sunroof, heated seats and a wireless phone charger. The new Dolphin model comes with the same battery range of 350 km (217 miles) as the other Dolphin models.
Deliveries of the new Dolphin model are set to begin in March.
You may not be a billionaire like Warren Buffett, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/25/01/42798998/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: BYD is one of the largest electric vehicle companies in the world, selling 4.27 million new energy vehicles globally, which includes electric vehicles and plug-in hybrids, in 2024. This total was up 41% year-over-year.
In Australia, BYD ranked second for 2024 EV sales and had a 14.6% year-over-year gain in units sold. Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) ranked first in 2024 with a market share of 42% of EVs in Australia, but saw its year-over-year sales decline 16.8%, as <a href="https://www.drive.com.au/news/australias-best-selling-electric-cars-2024/">reported </a>by Drive.
Other EV companies like BYD saw their sales gain 28.8% year-over-year while Tesla fell, helping to set a record in Australia for a sixth straight year. The country had 91,292 EVs sold across cars, SUVs and light commercial vehicles, up 4.7% year-over-year and representing 7.4% of all new vehicles sold in the year.
EV sales faced pressure in Australia in the second half of 2024 with an overall drop of 6.9% year-over-year, with Tesla sales falling 25.8% year-over-year and other EV models gaining 9.6% year-over-year.
Tesla had the top two selling vehicles in Australia in 2024 with the Model Y and model 3 ranking first and second respectively.
BYD had three of the top 10 selling EVs in the country with the Seal, Atto 3 and Dolphin ranking fourth, fifth and eighth respectively.
A new lower-priced Dolphin could continue to cut into Tesla's market share. The EV company has watched its market share in Australia fall from 59% in 2022 to 53% in 2023 to 42% in 2024.
The Shark, which is BYD's first pickup truck, has over 5,500 preorders placed according to the report and deliveries begin soon. BYD will also launch the new Sealion 07, which is called a Model Y competitor. The Sealion 07 starts at under $60,000, falling in similar range of the Model Y, which starts at $55,900.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/25/01/42832123/warren-buffett-beats-sp-500-in-2024-how-oracle-of-omahas-returns-compare-over-past-20-years">Warren Buffett Beats S&amp;P 500 In 2024, How Oracle Of Omaha&#8217;s Returns Compare Over Past 20 Years</a></li>
</ul>
BYD photo

Management

BYDDF

BYDDY

TSLA

Warren Buffett-Backed BYD Launches Australia's First EV Under $30K: How The Move Could Strengthen Fight Against Elon Musk's Tesla

Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares dipped 11.2% to $9.60 during Wednesday&#8217;s session, pulling back<a href="https://www.benzinga.com/topic/novavax"> following recent strength. </a>
Shares of vaccine makers are volatile this week after the first bird flu death was reported in the U.S. Additionally, a recent CDC <a href="https://www.cdc.gov/respiratory-viruses/data/index.html#cdc_data_surveillance_section_2-weekly-national-summary">report</a> noted an increase in acute respiratory illness activity.
What To Know: As a company specializing in vaccine development, Novavax is positioned as a potential player in addressing such outbreaks, particularly given its history of <a href="https://www.benzinga.com/general/biotech/24/09/40688052/fda-approves-novavaxs-updated-covid-vaccine-targeting-currently-circulating-variants">creating vaccines</a> for infectious diseases.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/42897161/apples-24-year-70000-climb-since-itunes-faces-2025-test">Apple&#8217;s 24-Year 70,000% Climb Since iTunes Launch Faces 2025 Test</a>
While <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">traditional bird flu vaccines</a> from Sanofi, CSL Seqirus and GlaxoSmithKline are already stockpiled, they target older H5N1 strains, leaving potential room for innovation and updates.
Novavax, with its proprietary recombinant nanoparticle vaccine technology, could be seen as a contender to develop a next-generation bird flu vaccine if demand grows. The bird flu outbreak, which has <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42471357/egg-hyperinflation-could-spike-grocery-prices-why-cal-maine-vital-farms-are-soaring">devastated poultry farms</a> and raised concerns about viral mutations, could also underscore the need for advanced vaccine platforms.
Investor speculation about potential government funding or contracts to combat the outbreak could likely contribute to volatility in Novavax shares, despite the CDC stating that <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">public risk remains low</a>.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies</a>
<h2 class="wp-block-heading">How To Buy NVAX Stock</h2>
By now you're likely curious about how to participate in the market for Novavax &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of Novavax, which is trading at $9.60 as of publishing time, $100 would buy you 10.41 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NVAX has a 52-week high of $23.86 and a 52-week low of $3.53.
Image courtesy of <a href="https://pixabay.com/illustrations/ai-generated-stock-exchange-bull-8477673/">Pixabay</a>

Health Care

NVAX

Why Novavax Stock Is Volatile This Week

James Howells, who is infamously known for having accidentally thrown away a hard drive containing 8,000 Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), has suffered a new setback in his quest to <a href="https://www.benzinga.com/markets/cryptocurrency/22/08/28706518/meet-a-man-on-a-quest-to-find-about-180-million-in-bitcoin-buried-in-a-landfill">reclaim his fortune</a>.
What Happened: A high court ruling by Judge Keyser KC has dismissed James Howells&#8217; legal claim to recover the hard drive, citing no &#8220;reasonable grounds&#8221; for bringing the claim and &#8220;no realistic prospect&#8221; of winning it.
Howells, who had sued the Newport City Council in Wales over the case, said he was &#8220;very upset&#8221; after the ruling, saying &#8220;it&#8217;s the great British injustice system striking again.&#8221;
After trying for 12 years to recover the lost coins, the ruling felt like &#8220;a kick in the teeth,&#8221; Howells lamented.
The case stems from an incident in 2013 when Howells accidentally threw away a hard drive containing 8,000 BTC.
The hard drive was discarded in a landfill in Newport, Wales, and Howells sought permission from Newport Council to <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41308908/man-who-accidentally-threw-hard-drive-containing-8-000-bitcoins-worth-half-a-billion-dolla">excavate the site</a> in order to recover it.
However, the council rejected his request, and the court ruled that the council&#8217;s environmental permits prohibit excavation.
James Goudie KC, representing the council, argued that once the hard drive entered the landfill, it became the council's property.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42881109/bitcoin-is-suffering-from-a-shift-in-macro-expectations-analyst-says-heres-what-that-means">Bitcoin Is Suffering From A Shift In Macro Expectations, Analyst Says: Here&#8217;s What That Means</a>
Why It Matters: At the current market price of $93,128.86, the 8,000 Bitcoins on the discarded hard drive are worth about $745.03 million. 
This is a significant decrease compared to mid-December 2024, when Bitcoin's value peaked at $108,268.45.
Howells had repeatedly requested permission from the council to access the landfill site, offering a share of the Bitcoin in exchange for its recovery. 
Despite his persistent efforts, the court&#8217;s ruling has put an end to his claims.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42900509/social-media-sentiment-report-shows-only-one-out-of-bitcoin-xrp-dogecoin-is-bullish">Social Media Sentiment Report Shows Only One Out Of Bitcoin, XRP, Dogecoin Is Bullish</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Man Who Accidentally Threw Away 8,000 Bitcoin Hard Drive Suffers New 'Kick In The Teeth' As UK Court Dismisses His Claim

Fifth Third Bancorp's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NYSE">FITB</a>) short percent of float has fallen 4.65% since its last report. The company recently reported that it has 18.81 million shares sold short, which is 3.28% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.86 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Fifth Third Bancorp Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736451022_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Fifth Third Bancorp has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Fifth Third Bancorp's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Fifth Third Bancorp's peer group average for short interest as a percentage of float is 0.96%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

FITB

Looking Into Fifth Third Bancorp's Recent Short Interest

Tonix Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NYSE">TNXP</a>) short percent of float has risen 151.76% since its last report. The company recently reported that it has 4.00 million shares sold short, which is 2.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tonix Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736451017_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tonix Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tonix Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tonix Pharmaceuticals's peer group average for short interest as a percentage of float is 4.81%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

TNXP

(TNXP) - Analyzing Tonix Pharmaceuticals's Short Interest

JPMorgan Chase's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) short percent of float has fallen 4.59% since its last report. The company recently reported that it has 29.19 million shares sold short, which is 1.04% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.86 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>JPMorgan Chase Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736451012_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for JPMorgan Chase has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing JPMorgan Chase's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, JPMorgan Chase's peer group average for short interest as a percentage of float is 1.06%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(JPM) - Analyzing JPMorgan Chase's Short Interest

In the current market session, Select Medical Hldgs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) share price is at $18.73, after a 0.48% increase. Moreover, over the past month, the stock decreased by 5.59%, but in the past year, spiked by 31.69%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1736450112_0.png" alt="Past Year Chart" />

<h3>Select Medical Hldgs P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 25.68 in the Health Care Providers &amp; Services industry, Select Medical Hldgs Inc. has a lower P/E ratio of 8.75. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1736450112_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

Price Over Earnings Overview: Select Medical Hldgs

<a href="https://www.ft.com/content/38c519c3-1fe9-4d2c-9d8c-6dd158ab35aa" title="https://www.ft.com/content/38c519c3-1fe9-4d2c-9d8c-6dd158ab35aa">https://www.ft.com/content/38c519c3-1fe9-4d2c-9d8c-6dd158ab35aa</a>

Politics

General

OKLO

Report From Jan. 3 "US relaxes green hydrogen rules in race to boost sector" -Financial Times

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping <a target="_blank" href="https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more" rel="noreferrer noopener">investor outlook for 2025</a>.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector&#8217;s performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500&#8217;s 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Ahead of the 2025 JPM Healthcare Conference, JP Morgan highlights some investor expectations as sentiment remains mixed for the US Large Cap BioPharma group heading into 2025. The conference is scheduled between 13 January and 16 January.
Obesity is expected to remain a major focus for the industry. The sector&#8217;s focus on the below advancements highlights the growing importance of obesity treatments and related drug innovations:
<ul>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>): Increased emphasis on incretin therapies as production capacity grows and direct-to-consumer advertising gains traction. Key data catalysts: Phase 3 results for orforglipron, an oral <a href="https://www.benzinga.com/general/biotech/23/07/33339766/ozempic-alternatives-these-two-drugs-show-promise-in-affordability-and-effectiveness-for-weight-l" target="_blank" rel="noreferrer noopener">small molecule GLP-1</a>.</li>
<li>Initial outcomes data for tirzepatide <a href="https://www.benzinga.com/general/biotech/24/08/40460727/eli-lillys-famed-obesitydiabetes-treatment-tirzepatide-shows-potential-to-cut-risk-of-developing-" target="_blank" rel="noreferrer noopener">in type 2 diabetes</a>.</li>
</ul>
Several new product launches are on the radar for 2025. Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) stands out as a top pick, with the anticipated launch of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea" rel="noreferrer noopener">Cobenfy for schizophrenia</a>.
JP Morgan analyst Chris Schott expects a strong adoption once broader insurance coverage, expected by the second half of 2025, is in place.
Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is also preparing for a mid-2025 launch of lenacapavir for pre-exposure prophylaxis, with promising uptake <a target="_blank" href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" rel="noreferrer noopener">projected into 2026</a>.
Additionally, JP Morgan is monitoring Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Winrevair for pulmonary arterial hypertension, which has already <a target="_blank" href="https://www.benzinga.com/25/01/42768614/uk-approves-mercks-hypertension-drug-acquired-via-11-billion-acceleron-pharma-deal" rel="noreferrer noopener">exceeded early expectations</a>, and Gilead&#8217;s Livdelzi for primary biliary cholangitis, expected to see more significant growth in 2025 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42016935/gilead-unveils-long-term-data-from-seladelpar-in-patients-with-rare-liver-disease" rel="noreferrer noopener">as access improves</a>.
The analyst is watching for updates on how companies are approaching business development after a relatively quiet 2024. While major changes are not anticipated in the size or type of deals pursued by large-cap companies, JP Morgan expects M&amp;A activity to pick up in 2025.
Large deals over $25 billion remain unlikely, with mid-sized deals around $5-15 billion likely to focus on later-stage, lower-risk assets.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42898400/sanofis-blood-cancer-drugs-new-subcutaneous-formulation-hits-primary-goal-in-late-stage-in-multiple-myeloma" target="_blank" rel="noreferrer noopener">Sanofi&#8217;s Blood Cancer Drug&#8217;s New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma</a></li>
</ul>
Image via Shutterstock

Analyst Color

Biotech

Large Cap

Analyst Ratings

AMGN

GILD

REGN

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference

Marvell Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) shares are trading higher by some 7% to $118.23 over the trailing week. JPMorgan analyst Harlan Sur this week <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42859614/jpmorgan-sees-marvells-ai-revenue-surge-with-2-billion-run-rate-in-networking-by-2025">provided an optimistic outlook</a> for the company, highlighting the company's strong momentum in AI-driven growth.
Marvell also unveiled its <a href="https://www.benzinga.com/news/25/01/42820909/whats-going-on-with-marvell-technology-mrvl-stock">custom XPU architecture</a>, integrating co-packaged optics to enhance AI server scalability with superior data transmission reach and energy efficiency.
What To Know: Sur <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42859614/jpmorgan-sees-marvells-ai-revenue-surge-with-2-billion-run-rate-in-networking-by-2025">highlighted</a> that Marvell is set to surpass its $2.5 billion AI revenue target for CY25, fueled by robust demand for optical and copper networking products and AI ASIC programs with Amazon and Google.
Read Also: <a href="https://www.benzinga.com/25/01/42899028/la-wildfire-damages-estimated-above-52-billion-california-property-insurance-crisis">LA Wildfire Damages Could Top $52 Billion As California Faces Property Insurance Crisis</a>
The company is also expanding into scale-up networking with advanced solutions like active electrical cables, co-packaged optics and linear pluggable optics.
Sur noted Marvell's partnership with Amazon remained solid, with expectations of sustained multi-generational product wins. Despite competition from Amazon's 3nm AI compute ASIC program, Marvell anticipated no revenue disruptions through CY26, projecting continued growth.
Sur also described the company's $8 billion AI Custom ASIC revenue target for CY28 as conservative given the market's rapid expansion.
Read Also: <a href="https://www.benzinga.com/general/market-summary/25/01/42895251/mrvl-stock-has-gained-over-7-in-last-five-sessions-as-marvell-technologys-new-chip-boosts-ai-server-performance-heres-what-technical-analysis-says">MRVL Stock Has Gained Over 7% In Last Five Sessions As Marvell Technology&#8217;s New Chip Boosts AI Server Performance: Here&#8217;s What Technical Analysis Says</a>
<h1 class="wp-block-heading">Is MRVL A Good Stock To Buy?</h1>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages — such as <a href="https://www.benzinga.com/quote/MRVL">Marvell</a>&#8216;s page for example — there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Marvell Tech does pay a dividend, which yields 0.31% per year as of the closing price on Jan. 9, 2025. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 18.34%, you'll need to buy a share of Orchid Island Cap by Jan. 31, 2025. Once done, you can expect to receive a nominal payout of $0.12 on Feb. 12, 2025.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/MRVL">Marvell</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, MRVL has a 52-week high of $126.12 and a 52-week low of $53.19.
Image courtesy of <a href="http://Pixabay">Pixabay</a>

Movers

Tech

MRVL

What's Going On With Marvell Technology (MRVL) Stock?

As Washington ramps up chip export restrictions to unfriendly countries, Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) are in the midst of a geopolitical power shift that could disrupt the semiconductor <a href="https://www.benzinga.com/topic/semiconductors">industry&#8217;s global landscape.</a>
In a report shared Monday, Bloomberg outlined the Biden administration&#8217;s imminent release of updated export <a href="https://www.benzinga.com/government/regulations/25/01/42897081/nvidia-and-ai-chip-stocks-brace-for-impact-as-biden-administration-considers-new-china-export-ban-report">rules targeting advanced semiconductors. </a>
The new measures, expected to drop Friday, intensify the U.S.&#8217;s strategic efforts to slow China's technological and military advancements by restricting access to high-performance computing chips.
<h3 class="wp-block-heading">New AI Export Framework: Allies And Adversaries</h3>
The regulations will reportedly create a three-tiered structure for semiconductor exports, emphasizing access tiers for key U.S. allies, neutral nations, and restricted countries. 
China is expected to fall under the most severe tier, joining nations such as Russia, Iran, and Venezuela.
This tier-based framework allows certain companies in restricted countries to bypass national limits by agreeing to U.S. security protocols and human rights standards. 
These entities, designated as validated end users, would have higher caps for chip purchases, a move aimed at encouraging safer AI development globally.
The measures expand the sweeping export restrictions initiated in October 2022, which already limited sales of advanced AI chips like Nvidia's Hopper GPUs. 
These earlier rules also prohibited U.S. firms and individuals from supporting Chinese chip development without explicit government approval. 
<h3 class="wp-block-heading">Nvidia And AMD Under Scrutiny</h3>
Nvidia's specialized A800 and H800 chips, developed to comply with prior regulations, could now fall under new restrictions, potentially denting AI giant&#8217;s upcoming revenues. 
According to data firm FactSet, China accounts for approximately 16% of Nvidia&#8217;s revenue, making it the company's second-largest market after the U.S. This marks a decline from 25% prior to the 2022 export restrictions.
In 2023, AMD generated roughly $3.4 billion in revenue from China, including Hong Kong, according to Statista. This represents 15% of the company&#8217;s total revenue of $22.7 billion.
<h3 class="wp-block-heading">Key ETFs Tied To Nvidia And AMD</h3>
Several ETFs heavily exposed to Nvidia and AMD could face ripple effects:
Top ETFs Holding Nvidia (Percentage of Holdings):
<ul>
<li>ProShares Ultra Semiconductors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USD#NYSE">USD</a>): 34.96%</li>
<li>Strive U.S. Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOC#NASDAQ">SHOC</a>): 21.10%</li>
<li>YieldMax Target 12 Semiconductor Option (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXY#NASDAQ">SOXY</a>): 20.50%</li>
<li>VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>): 20.21%</li>
<li>VanEck Fabless Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMHX#NASDAQ">SMHX</a>) – 20.11%</li>
</ul>
Top ETFs Holding AMD (Percentage of Holdings):
<ul>
<li>VanEck Video Gaming and Esports ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPO#NASDAQ">ESPO</a>): 8.01%</li>
<li>iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>): 7.12%</li>
<li>AOT Growth and Innovation ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOTG#NASDAQ">AOTG</a>): 7.07%</li>
<li>Invesco PHLX Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXQ#NASDAQ">SOXQ</a>): 7.04%</li>
<li>REX FANG &amp; Innovation Equity ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEPI#NASDAQ">FEPI</a>): 6.95%</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42888800/goldman-sachs-flags-market-correction-risk-as-inflation-trump-policies-stir-uncertainty">Goldman Sachs Flags Market Correction Risk As Inflation, Trump Policies Stir Uncertainty</a></li>
</ul>
Image created using photos from Shutterstock.

Asia

Government

Regulations

Sector ETFs

Global

ETFs

AOTG

ESPO

FEPI

NVDA

EA Series Trust Strive U.S. Semiconductor ETF

SHOC

SMHX

SOXQ

iShares PHLX SOX Semiconductor Sector Index Fund

Comments

Permian Resources

Actualités

Dernières nouvelles pour Permian Resources (NYSE:PR) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL